TQB 3117
Alternative Names: TQB-3117Latest Information Update: 01 Jun 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 16 May 2024 Preclinical trials in Cancer in China (PO) prior to May 2024
- 16 May 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase-I trial for Cancer (Late-stage disease) in China in June 2024 (PO), (NCT06415903)